Galderma Group AG (VIE:GALD)

Market Cap	37.64B +33.3%
Revenue (ttm)	4.46B +18.0%
Net Income	522.09M +165.4%
EPS	2.20 +166.0%
Shares Out	n/a
PE Ratio	72.10
Forward PE	40.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	28
Open	161.00
Previous Close	161.00
Day's Range	161.00 - 161.00
52-Week Range	149.00 - 180.00
Beta	n/a
RSI	44.16
Earnings Date	Mar 5, 2026

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 19...

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 7,676
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: GALD

Financial Performance

In 2025, Galderma Group AG's revenue was $5.24 billion, an increase of 18.04% compared to the previous year's $4.44 billion. Earnings were $613.00 million, an increase of 165.37%.

Financial numbers in USD